Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Copley Scientific to showcase new TPKâ„¢ 2100 Critical Flow Controller for dry powder inhaler testing at DDL2017

Copley Scientific
Posted on: 28 Nov 17
Copley Scientific to showcase new TPKâ„¢ 2100 Critical Flow Controller for dry powder inhaler testing at DDL2017

Tuesday 28th November: Nottingham, UK: Copley Scientific, the world’s leading manufacturer of inhaler test equipment, will be presenting its new 3rd generation Critical Flow Controller – the TPK™ 2100 – for the testing of dry powder inhalers (DPIs) at the 2017 Drug Delivery to the Lungs conference (DDL2017) in Edinburgh. Now in its 27th year, DDL is the premier annual event for researchers in the field. The company is showcasing this latest TPK™ model at DDL to highlight a series of new capabilities, all intended to make dry powder inhaler testing more automated, more reproducible and more efficient.

For DDL2017, more than 700 delegates and 90 industry sponsors are expected for the 3-day meeting, which will feature discussions on industry hot topics as diverse as the lessons formulators can learn from new e-cigarettes, as well as a regulatory update presentation from the European Medicines Agency (EMA).

The newly introduced TPK™ 2100 builds on Copley’s heritage of TPK™ models, an international standard in the field of DPI testing equipment, and is ideally suited to the needs of formulators and quality control scientists. It sets a new benchmark for the set-up, control and documentation of all the parameters associated with the measurement of delivered dose uniformity and aerodynamic particle size distribution (APSD) by cascade impaction, in accordance with the United States and European Pharmacopoeias.

Anna Sipitanou, Business Development Manager at Copley Scientific, comments:

“The new TPK 2100™ has already generated extremely positive feedback from customers who have interacted with it, both at RDD Europe back in April and since its launch. We think it will be a big hit at DDL, as we give live demonstrations to inhaler testing analysts and laboratory managers alike. It is rewarding to know that the advancements we have incorporated into the TPK™ 2100 look set to benefit both existing and new customers, making a substantial difference to productivity and efficiency in the execution of these important tests.” 

Designed to replace the well-established TPK™ 2000, significant new features are built into the TPK™ 2100. A new ‘fly-by-wire’ flow control valve allows operation to be automated. Inhaler pressure drop, P1, and test flow rate are accurately and rapidly set by the TPK™ 2100 during test set-up, whilst in-line flow measurement can be accommodated and in-situ impactor leak testing is fully automated for the first time. The user is warned if the important P3/P2 ratio is greater than 0.5, giving full confidence that tests are conducted under sonic flow conditions, whilst notification is also given if the set flow rate and impactor leak rate are outside acceptance limits. Test duration is automatically calculated based on the required test volume, and the new model offers an optional footswitch and temperature/humidity module. Data output to printer and computer are standard, with enhanced monitoring and 5 different reports covering critical in-test parameters, whilst remote control via USB allows the TPK™ 2100 to be integrated into larger automated systems, where required. Finally, the new instrument allows users to emulate the previous generations of TPK™, promoting interchangeability and integration into existing standard operating procedures (SOPs).

A new TPK™ 2100-R is also being launched. This is a reversed version where the flow inlet and outlets are swapped over to allow for different arrangements of testing equipment to be set up on the laboratory bench.

Experts from Copley Scientific will on hand throughout DDL2017 to discuss any aspect of inhaler testing. Visit stand 246 or, to find out more about the TPK™ 2100, contact: sales@copleyscientific.co.uk

To see Copley’s full programme of equipment for inhaled drug testing, download ‘Quality Solutions for Inhaled Testing’ from: http://www.copleyscientific.com/downloads/brochures

ENDS

About Copley Scientific

Copley Scientific is recognised as the world’s leading manufacturer and supplier of inhaler test equipment and is a major provider of testing systems for other pharmaceutical dosage forms. The company is also active in detergent testing, air sampling and aerosol characterisation.

Copley Scientific’s pharmaceutical product range includes test equipment for: delivered dose uniformity and aerodynamic particle size measurement of metered-dose inhalers, dry powder inhalers, nebulizers and nasal sprays; as well as tablets (dissolution, disintegration, friability and hardness) capsules, powders, suppositories and transdermals.

Copley Scientific has offices in the UK and Switzerland. The company works in partnership with aerosol particle science experts MSP Corporation in North America, and also distributes MSP Corporation’s air sampling and aerosol characterisation products throughout Europe.

Serving the pharmaceutical and associated industries, Copley Scientific offers an extensive range of equipment for research, development and quality control, as well as full validation and aftersales services. This broad range of products is supplied and supported worldwide through a network of specialist distributors. www.copleyscientific.com

For further information:

Press information

Kapler Communications

1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, UK

Tel: +44 (0) 1477 539 545; Fax: +44 (0) 1477 539 540

copley@kapleronline.com

Company contact:

Mark Copley, Sales Director, Copley Scientific Limited

Colwick Quays Business Park, Private Road No. 2, Colwick, Nottingham

UK NG4 2JY

Tel: +44 (0)115 961 6229; Fax: +44 (0)115 961 7637

m.copley@copleyscientific.co.uk 

www.copleyscientific.com

European Office (Austria, France, Germany, Italy, Switzerland)

Copley Scientific AG
Erlenstrasse 27, Postfach 152, CH-4106 Therwil, Switzerland

Tel: +41 (0)61 725 25 35;  Fax: +41 (0)61 721 31 87
sales@copleyscientific.ch

www.copleyscientific.com

 

For more information:
www.copleyscientific.com

Editor's Details

Lizzie Randall
Kapler Communications
copley@kapleronline.com

Last updated on: 28/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.